Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation

British Journal of Clinical Pharmacology

Volumn 60, Issue 3, 2005, Pages 265-275

  Mulla, Hussain ^a,b   Pooboni, Suneel ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; CREATININE BLOOD LEVEL; DATA BASE; DRUG CLEARANCE; DRUG DISTRIBUTION; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; HUMAN TISSUE; INFANT; MALE; MEDICAL RECORD; MICROCLIMATE; NEWBORN; POPULATION MODEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY FAILURE; STEADY STATE; VALIDATION PROCESS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 24044530404     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02432.x     Document Type: Article

References (26)

1. Bartlett R, Roloff D, Custer J, Younger J, Hirschl R. Extracorporeal life support. The University of Michigan Experience. J Am Med Assoc 2000; 283: 904-8.
2. Peek G, Killer H, Sosnowski A, Firmin R. Extracorporeal membrane oxygenation: potential for adults and children? (Review). Hospital Med (London) 1998; 59: 304-8.
3. Mulla H, Lawson G, Firmin R, Upton D. Drug disposition during extracorporeal membrane oxygenation (ECMO). Paediatric Perinatal Drug Ther 2001; 4: 109-20.
4. Mulla H, Nabi F, Nichani S, Lawson G, Firmin R, Upton D. Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. Br J Clin Pharmacol 2003; 55: 23-31.
5. Mulla H, McCormack P, Lawson G, Firmin R, Upton D. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology; (in press).
6. Hoie E, Swigart S, Leuschen M. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharmacokinet 1990; 9: 711-5.
7. Amaker R, DiPiro J, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrobial Agents Chemother 1996; 40: 1139-42.
8. Buck M, Ksenich R, Wooldridge P. Vancomycin pharmacokinetics in neonates receiveing extracorporeal membrane oxygenation. Pharmacotherapy 1998; 18: 1082.
9. White LO, Holt HA, Reeves DS, MacGowan A. Evaluation of Innufluor fluorescence polarisation immunoassay kits for the determination of serum conceptions of gentamicin, tobramycin, amikacin and vancomycin. J Antimicrobial Chemother 1997; 39: 355-61.
10. Pharsight. Winnonmix Professional. In 2.0.1. eds. California 94040: Pharsight Corporation. 1993-2000.
11. Compaq. Compaq Visual Fortran Professional Edition. In 6.5., eds. Compaq Computer Corporation; September 2000.
12. Sheiner L, Beal S. Some suggestions for measuring predictive performance. J Pharmacokin Biopharm 1981; 9: 503-12.
13. Odio C, McCracken GJ, Nelson J. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatrics 1984; 105: 491-3.
14. Bhatt-Mehta V, Schumacher R, Faix R, Leady M, Brenner T. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case controlled study. Pediatrics 1999; 103: e48.
15. Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents Chemother 1998; 42: 2739-44.
16. Duffull S, Begg E, Chambers S, Barclay M. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrobial Agents Chemother 1994; 38: 2480-2.
17. Zimmermann A, Katona B, Plaisance K. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995; 15: 85-91.
18. Capparelli E, Lane J, Romanowski C, McFeely E, Murray W, Sousa P, Kildoo C. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001; 41: 927-34.
19. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomcyin in Japanese adult patients. Ther Drug Monit 1998; 20: 139-48.
20. Grimsley C, Thomson A. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Childhood Fetal Neonatal Edition 1999; 81: F221-F227.
21. Naqvi S, Keenan W, Reichley R, Fortune K. Vancomcyin pharmacokinetics in small, seriously ill infants. Am J Dis Childhood 1986; 140: 107-10.
22. Schaad U, McCracken G, Nelson J. Clinical pharmacology and efficacy of vancomcyin in pediatric patients. J Pediatrics 1980; 96: 119-26.
23. Rowland M, Tozer T. Clinical pharmacokinetics. Concepts and applications, 3rd edn. Philadelphia: Lippincott. Williams & Wilkins 1995.
24. Rodvold K, Blum R, Fischer J, Zokufa H, Rotschafer J, Crossley K, Riff L. Vancomcyin pharmacokinetics in patients with various degrees of renal function. Antimicrobial Agents Chemotherapy 1988; 32: 848-52.
25. Bartlett R. Extracorporeal life support for cardiopulmonary failure. Current Problems Surg 1990; 27: 621-705.
26. de Hoog M, Schoemaker R, Mouton J, van den Anker J. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Therapeutics 2000; 67: 360-7.